(15035714), T. K., (15050147), T. S., (14182957), Y. K., (16374908), K. S., (16540569), H. S. O., (16540572), T. S., . . . (15033972), K. Y. (2025). Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study.
Чикаго стиль цитування (17-те видання)(15035714), Takafumi Koyama, et al. Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study. 2025.
Стиль цитування MLA (9-ме видання)(15035714), Takafumi Koyama, et al. Supplementary Table S5B from Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with <i>MDM2</i> Amplification: An Open-Label Phase Ib/II Study. 2025.